1.0.0.0 AS­SESS­MENT OF GLYCEMIC CON­TROL

The Amer­i­can Di­a­betes As­so­ci­a­tion (ADA) “Stan­dards of Med­i­cal Care in Di­a­betes” in­cludes ADA’s cur­rent clin­i­cal prac­tice rec­om­men­da­tions and is in­tend­ed to pro­vide the com­po­nents of di­a­betes care, gen­er­al treat­ment goals and guide­lines, and tools to eval­u­ate qual­i­ty of care. Mem­bers of the ADA Pro­fes­sion­al Prac­tice Com­mit­tee, a mul­ti­dis­ci­plinary ex­pert com­mit­tee, are re­spon­si­ble for up­dat­ing the Stan­dards of Care an­nu­al­ly, or more fre­quent­ly as war­rant­ed. For a de­tailed de­scrip­tion of ADA stan­dards, state­ments, and re­ports, as well as the ev­i­dence-‍grad­ing sys­tem for ADA’s clin­i­cal prac­tice rec­om­men­da­tions, please refer to the Stan­dards of Care In­tro­duc­tion. Read­ers who wish to com­ment on the Stan­dards of Care are in­vit­ed to do so at pro­fes­sion­al.di­a­betes.org/‍SOC.

AS­SESS­MENT OF GLYCEMIC CON­TROL

Glycemic man­age­ment is pri­mar­i­ly as­sessed with the A1C test, which was the mea­sure stud­ied in clin­i­cal tri­als demon­strat­ing the benefits of im­proved glycemic con­trol. Pa­tient self-‍mon­i­tor­ing of blood glu­cose (SMBG) may help with self-‍man­age­ment and med­i­ca­tion ad­just­ment, par­tic­u­lar­ly in in­di­vid­u­als tak­ing in­sulin. Con­tin­u­ous glu­cose mon­i­tor­ing (CGM) also has an im­por­tant role in as­sess­ing the ef­fec­tive­ness and safe­ty of treat­ment in many pa­tients with type 1 di­a­betes, and lim­it­ed data sug­gest it may also be help­ful in se­lect­ed pa­tients with type 2 di­a­betes, such as those on in­ten­sive in­sulin reg­i­mens (1).